To advance scientific understanding of the kidney health and patient safety implications of new and existing medical products and to foster development of therapies for diseases that affect the kidney by creating a collaborative environment in which FDA and the greater nephrology community can interact to optimize evaluation of drugs, devices, biologics, and food products.
New KHI Projects and Workgroup Opportunities
The Kidney Health Initiative is pleased to announce two new projects and request participation on the project workgroups.
To learn more about these projects or to apply for the workgroup, click on the links provided. The deadline to apply for the workgroups is Thursday, February 20.
CJASN Special Feature
Read the press release announcing the new partnership:
Watch the Video
ASN Executive Director Tod Ibrahim provides an update on the early success of the Kidney Health Initiative. Watch video »
ASN President Ronald Falk, MD, FASN discusses the Society's collaboration with the FDA. Watch video »
Listen to the Podcast
This Kidney News podcast features ASN Executive Director Tod Ibrahim's interview with ASN President Ronald J. Falk, MD, FASN, on the Kidney Health Initiative (KHI), a new partnership between ASN and the U.S. Food and Drug Administration to advance kidney health. Dr. Falk describes how KHI will collaborate with patient support groups, professional organizations, industry groups and other stakeholders to foster development of new therapeutics and ensure the safety of drugs, devices, biologics, and food products for patients with kidney disease.
If you have any questions about KHI, or would like more information about becoming a member, please contact email@example.com.